SU‐FF‐J‐106: FMISO‐PET Hypoxia Imaging: A Novel Method to Plan IMRT‐Based Boost Radiation to Hypoxic Subvolumes

K. Hendrickson, J. Rajendran, E. Ford, P. Kinahan, B. Lewellen, M. Phillips, Kenneth Krohn

Research output: Contribution to journalArticle

Abstract

Purpose: To investigate the use of [F‐18] fluoromisonidazole (FMISO) PET and intensity modulated radiation treatment (IMRT) planning to escalate the dose to hypoxic subvolumes in patients with advanced head and neck tumors. Method and Materials: Seventy‐three patients with head and neck cancer underwent FMISO‐PET scans, with fifty‐three of them also undergoing FDG‐PET scans as part of ongoing research studies. An initial treatment plan used a PTV defined with a 0.5‐cm margin around physician‐defined primary GTVs and affected nodal systems. The prescription dose is 70 Gy to the PTV and 50 Gy to the affected nodes, while sparing the spinal cord, mandible, and parotid glands. Physician‐defined regions of enhanced FMISO signal were used to define boost volumes on coregistered FMISO‐PET/CT images. The boost plan prescription dose to the hypoxic subvolumes is an additional 10 Gy. Results: Initial results from example treatment plans for two head and neck cancer patients are as follows (average over patients): to the PTV V100 = 87.2%, Dmin = 6081 cGy, D10 = 7303 cGy and to the nodal system V100 = 95.9%, Dmin = 4764 cGy, D10 = 5280 cGy. The IMRT boost plan yields V100 = 95.1%, Dmin = 979 cGy, D10 = 1012 cGy to the hypoxic PTV. The critical structures of interest received the following dose distributions from the composite IMRT plans: cord D1 = 3890 cGy, left (contralateral) parotid gland D1 = 1965 cGy, right parotid gland D1 = 4907 cGy (same side as primary tumor), and mandible D5 = 6220 cGy. Conclusion: We demonstrate the feasibility of directing dose‐escalated IMRT to hypoxic subvolumes in head and neck cancer using coregistered FMISO‐PET and CT images. Ongoing research and patient studies are expected to provide conclusive information on the clinical role of this procedure.

Original languageEnglish (US)
Number of pages1
JournalMedical Physics
Volume32
Issue number6
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Radiation
Parotid Gland
Head and Neck Neoplasms
Mandible
Prescriptions
Therapeutics
Research
Hypoxia
Neoplasms
Spinal Cord
Neck
Head
fluoromisonidazole

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

SU‐FF‐J‐106 : FMISO‐PET Hypoxia Imaging: A Novel Method to Plan IMRT‐Based Boost Radiation to Hypoxic Subvolumes. / Hendrickson, K.; Rajendran, J.; Ford, E.; Kinahan, P.; Lewellen, B.; Phillips, M.; Krohn, Kenneth.

In: Medical Physics, Vol. 32, No. 6, 2005.

Research output: Contribution to journalArticle

Hendrickson, K. ; Rajendran, J. ; Ford, E. ; Kinahan, P. ; Lewellen, B. ; Phillips, M. ; Krohn, Kenneth. / SU‐FF‐J‐106 : FMISO‐PET Hypoxia Imaging: A Novel Method to Plan IMRT‐Based Boost Radiation to Hypoxic Subvolumes. In: Medical Physics. 2005 ; Vol. 32, No. 6.
@article{74888685b7564d77b1ecc0f3cfc1b781,
title = "SU‐FF‐J‐106: FMISO‐PET Hypoxia Imaging: A Novel Method to Plan IMRT‐Based Boost Radiation to Hypoxic Subvolumes",
abstract = "Purpose: To investigate the use of [F‐18] fluoromisonidazole (FMISO) PET and intensity modulated radiation treatment (IMRT) planning to escalate the dose to hypoxic subvolumes in patients with advanced head and neck tumors. Method and Materials: Seventy‐three patients with head and neck cancer underwent FMISO‐PET scans, with fifty‐three of them also undergoing FDG‐PET scans as part of ongoing research studies. An initial treatment plan used a PTV defined with a 0.5‐cm margin around physician‐defined primary GTVs and affected nodal systems. The prescription dose is 70 Gy to the PTV and 50 Gy to the affected nodes, while sparing the spinal cord, mandible, and parotid glands. Physician‐defined regions of enhanced FMISO signal were used to define boost volumes on coregistered FMISO‐PET/CT images. The boost plan prescription dose to the hypoxic subvolumes is an additional 10 Gy. Results: Initial results from example treatment plans for two head and neck cancer patients are as follows (average over patients): to the PTV V100 = 87.2{\%}, Dmin = 6081 cGy, D10 = 7303 cGy and to the nodal system V100 = 95.9{\%}, Dmin = 4764 cGy, D10 = 5280 cGy. The IMRT boost plan yields V100 = 95.1{\%}, Dmin = 979 cGy, D10 = 1012 cGy to the hypoxic PTV. The critical structures of interest received the following dose distributions from the composite IMRT plans: cord D1 = 3890 cGy, left (contralateral) parotid gland D1 = 1965 cGy, right parotid gland D1 = 4907 cGy (same side as primary tumor), and mandible D5 = 6220 cGy. Conclusion: We demonstrate the feasibility of directing dose‐escalated IMRT to hypoxic subvolumes in head and neck cancer using coregistered FMISO‐PET and CT images. Ongoing research and patient studies are expected to provide conclusive information on the clinical role of this procedure.",
author = "K. Hendrickson and J. Rajendran and E. Ford and P. Kinahan and B. Lewellen and M. Phillips and Kenneth Krohn",
year = "2005",
doi = "10.1118/1.1997652",
language = "English (US)",
volume = "32",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TY - JOUR

T1 - SU‐FF‐J‐106

T2 - FMISO‐PET Hypoxia Imaging: A Novel Method to Plan IMRT‐Based Boost Radiation to Hypoxic Subvolumes

AU - Hendrickson, K.

AU - Rajendran, J.

AU - Ford, E.

AU - Kinahan, P.

AU - Lewellen, B.

AU - Phillips, M.

AU - Krohn, Kenneth

PY - 2005

Y1 - 2005

N2 - Purpose: To investigate the use of [F‐18] fluoromisonidazole (FMISO) PET and intensity modulated radiation treatment (IMRT) planning to escalate the dose to hypoxic subvolumes in patients with advanced head and neck tumors. Method and Materials: Seventy‐three patients with head and neck cancer underwent FMISO‐PET scans, with fifty‐three of them also undergoing FDG‐PET scans as part of ongoing research studies. An initial treatment plan used a PTV defined with a 0.5‐cm margin around physician‐defined primary GTVs and affected nodal systems. The prescription dose is 70 Gy to the PTV and 50 Gy to the affected nodes, while sparing the spinal cord, mandible, and parotid glands. Physician‐defined regions of enhanced FMISO signal were used to define boost volumes on coregistered FMISO‐PET/CT images. The boost plan prescription dose to the hypoxic subvolumes is an additional 10 Gy. Results: Initial results from example treatment plans for two head and neck cancer patients are as follows (average over patients): to the PTV V100 = 87.2%, Dmin = 6081 cGy, D10 = 7303 cGy and to the nodal system V100 = 95.9%, Dmin = 4764 cGy, D10 = 5280 cGy. The IMRT boost plan yields V100 = 95.1%, Dmin = 979 cGy, D10 = 1012 cGy to the hypoxic PTV. The critical structures of interest received the following dose distributions from the composite IMRT plans: cord D1 = 3890 cGy, left (contralateral) parotid gland D1 = 1965 cGy, right parotid gland D1 = 4907 cGy (same side as primary tumor), and mandible D5 = 6220 cGy. Conclusion: We demonstrate the feasibility of directing dose‐escalated IMRT to hypoxic subvolumes in head and neck cancer using coregistered FMISO‐PET and CT images. Ongoing research and patient studies are expected to provide conclusive information on the clinical role of this procedure.

AB - Purpose: To investigate the use of [F‐18] fluoromisonidazole (FMISO) PET and intensity modulated radiation treatment (IMRT) planning to escalate the dose to hypoxic subvolumes in patients with advanced head and neck tumors. Method and Materials: Seventy‐three patients with head and neck cancer underwent FMISO‐PET scans, with fifty‐three of them also undergoing FDG‐PET scans as part of ongoing research studies. An initial treatment plan used a PTV defined with a 0.5‐cm margin around physician‐defined primary GTVs and affected nodal systems. The prescription dose is 70 Gy to the PTV and 50 Gy to the affected nodes, while sparing the spinal cord, mandible, and parotid glands. Physician‐defined regions of enhanced FMISO signal were used to define boost volumes on coregistered FMISO‐PET/CT images. The boost plan prescription dose to the hypoxic subvolumes is an additional 10 Gy. Results: Initial results from example treatment plans for two head and neck cancer patients are as follows (average over patients): to the PTV V100 = 87.2%, Dmin = 6081 cGy, D10 = 7303 cGy and to the nodal system V100 = 95.9%, Dmin = 4764 cGy, D10 = 5280 cGy. The IMRT boost plan yields V100 = 95.1%, Dmin = 979 cGy, D10 = 1012 cGy to the hypoxic PTV. The critical structures of interest received the following dose distributions from the composite IMRT plans: cord D1 = 3890 cGy, left (contralateral) parotid gland D1 = 1965 cGy, right parotid gland D1 = 4907 cGy (same side as primary tumor), and mandible D5 = 6220 cGy. Conclusion: We demonstrate the feasibility of directing dose‐escalated IMRT to hypoxic subvolumes in head and neck cancer using coregistered FMISO‐PET and CT images. Ongoing research and patient studies are expected to provide conclusive information on the clinical role of this procedure.

UR - http://www.scopus.com/inward/record.url?scp=85024825561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024825561&partnerID=8YFLogxK

U2 - 10.1118/1.1997652

DO - 10.1118/1.1997652

M3 - Article

AN - SCOPUS:85024825561

VL - 32

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -